|
Gene: PARK7 |
Gene summary for PARK7 |
Gene summary. |
Gene information | Species | Human | Gene symbol | PARK7 | Gene ID | 11315 |
Gene name | Parkinsonism associated deglycase | |
Gene Alias | DJ-1 | |
Cytomap | 1p36.23 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q99497 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
11315 | PARK7 | GSM4909280 | Human | Breast | Precancer | 8.34e-03 | -7.08e-01 | 0.0305 |
11315 | PARK7 | GSM4909282 | Human | Breast | IDC | 2.36e-03 | -1.76e-01 | -0.0288 |
11315 | PARK7 | GSM4909286 | Human | Breast | IDC | 4.14e-10 | -2.26e-01 | 0.1081 |
11315 | PARK7 | GSM4909288 | Human | Breast | IDC | 6.84e-08 | 1.83e-01 | 0.0988 |
11315 | PARK7 | GSM4909294 | Human | Breast | IDC | 1.80e-25 | 2.39e-01 | 0.2022 |
11315 | PARK7 | GSM4909296 | Human | Breast | IDC | 1.37e-22 | 1.21e-01 | 0.1524 |
11315 | PARK7 | GSM4909297 | Human | Breast | IDC | 2.54e-33 | -1.73e-01 | 0.1517 |
11315 | PARK7 | GSM4909301 | Human | Breast | IDC | 3.28e-02 | -5.28e-02 | 0.1577 |
11315 | PARK7 | GSM4909302 | Human | Breast | IDC | 9.26e-05 | 6.97e-02 | 0.1545 |
11315 | PARK7 | GSM4909306 | Human | Breast | IDC | 2.25e-09 | 3.74e-01 | 0.1564 |
11315 | PARK7 | GSM4909308 | Human | Breast | IDC | 2.07e-08 | 2.84e-01 | 0.158 |
11315 | PARK7 | GSM4909309 | Human | Breast | IDC | 1.85e-05 | -2.13e-02 | 0.0483 |
11315 | PARK7 | GSM4909311 | Human | Breast | IDC | 4.07e-67 | -6.99e-01 | 0.1534 |
11315 | PARK7 | GSM4909312 | Human | Breast | IDC | 1.30e-28 | -4.53e-01 | 0.1552 |
11315 | PARK7 | GSM4909313 | Human | Breast | IDC | 2.19e-02 | -1.80e-01 | 0.0391 |
11315 | PARK7 | GSM4909315 | Human | Breast | IDC | 4.09e-04 | 8.67e-02 | 0.21 |
11315 | PARK7 | GSM4909316 | Human | Breast | IDC | 4.23e-12 | 1.80e-01 | 0.21 |
11315 | PARK7 | GSM4909318 | Human | Breast | IDC | 1.42e-09 | 3.34e-01 | 0.2031 |
11315 | PARK7 | GSM4909319 | Human | Breast | IDC | 1.81e-78 | -5.18e-01 | 0.1563 |
11315 | PARK7 | GSM4909320 | Human | Breast | IDC | 2.30e-05 | -3.39e-01 | 0.1575 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00183945 | Esophagus | HGIN | peptidyl-lysine acetylation | 39/2587 | 169/18723 | 7.46e-04 | 9.90e-03 | 39 |
GO:00101557 | Esophagus | HGIN | regulation of proton transport | 10/2587 | 24/18723 | 7.66e-04 | 1.00e-02 | 10 |
GO:00514095 | Esophagus | HGIN | response to nitrosative stress | 6/2587 | 10/18723 | 8.81e-04 | 1.13e-02 | 6 |
GO:003051818 | Esophagus | HGIN | intracellular steroid hormone receptor signaling pathway | 29/2587 | 116/18723 | 9.06e-04 | 1.15e-02 | 29 |
GO:005140219 | Esophagus | HGIN | neuron apoptotic process | 52/2587 | 246/18723 | 1.01e-03 | 1.26e-02 | 52 |
GO:00725959 | Esophagus | HGIN | maintenance of protein localization in organelle | 14/2587 | 42/18723 | 1.05e-03 | 1.31e-02 | 14 |
GO:000911720 | Esophagus | HGIN | nucleotide metabolic process | 92/2587 | 489/18723 | 1.11e-03 | 1.36e-02 | 92 |
GO:200011720 | Esophagus | HGIN | negative regulation of cysteine-type endopeptidase activity | 23/2587 | 86/18723 | 1.12e-03 | 1.37e-02 | 23 |
GO:000675320 | Esophagus | HGIN | nucleoside phosphate metabolic process | 93/2587 | 497/18723 | 1.25e-03 | 1.49e-02 | 93 |
GO:009723720 | Esophagus | HGIN | cellular response to toxic substance | 30/2587 | 124/18723 | 1.32e-03 | 1.57e-02 | 30 |
GO:00435435 | Esophagus | HGIN | protein acylation | 51/2587 | 243/18723 | 1.33e-03 | 1.57e-02 | 51 |
GO:005134827 | Esophagus | HGIN | negative regulation of transferase activity | 55/2587 | 268/18723 | 1.51e-03 | 1.74e-02 | 55 |
GO:007138320 | Esophagus | HGIN | cellular response to steroid hormone stimulus | 44/2587 | 204/18723 | 1.56e-03 | 1.79e-02 | 44 |
GO:004315419 | Esophagus | HGIN | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 21/2587 | 78/18723 | 1.65e-03 | 1.82e-02 | 21 |
GO:00064755 | Esophagus | HGIN | internal protein amino acid acetylation | 36/2587 | 160/18723 | 1.87e-03 | 2.01e-02 | 36 |
GO:00108228 | Esophagus | HGIN | positive regulation of mitochondrion organization | 20/2587 | 74/18723 | 2.00e-03 | 2.12e-02 | 20 |
GO:190305119 | Esophagus | HGIN | negative regulation of proteolysis involved in cellular protein catabolic process | 18/2587 | 64/18723 | 2.03e-03 | 2.13e-02 | 18 |
GO:004586126 | Esophagus | HGIN | negative regulation of proteolysis | 68/2587 | 351/18723 | 2.21e-03 | 2.28e-02 | 68 |
GO:009886920 | Esophagus | HGIN | cellular oxidant detoxification | 25/2587 | 101/18723 | 2.29e-03 | 2.34e-02 | 25 |
GO:005110125 | Esophagus | HGIN | regulation of DNA binding | 28/2587 | 118/18723 | 2.54e-03 | 2.51e-02 | 28 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0501224 | Breast | IDC | Parkinson disease | 107/867 | 266/8465 | 2.57e-39 | 8.36e-37 | 6.26e-37 | 107 |
hsa0502223 | Breast | IDC | Pathways of neurodegeneration - multiple diseases | 116/867 | 476/8465 | 3.63e-20 | 1.18e-18 | 8.82e-19 | 116 |
hsa0501234 | Breast | IDC | Parkinson disease | 107/867 | 266/8465 | 2.57e-39 | 8.36e-37 | 6.26e-37 | 107 |
hsa0502233 | Breast | IDC | Pathways of neurodegeneration - multiple diseases | 116/867 | 476/8465 | 3.63e-20 | 1.18e-18 | 8.82e-19 | 116 |
hsa0501243 | Breast | DCIS | Parkinson disease | 106/846 | 266/8465 | 1.64e-39 | 5.29e-37 | 3.90e-37 | 106 |
hsa0502243 | Breast | DCIS | Pathways of neurodegeneration - multiple diseases | 114/846 | 476/8465 | 4.74e-20 | 1.53e-18 | 1.13e-18 | 114 |
hsa0501253 | Breast | DCIS | Parkinson disease | 106/846 | 266/8465 | 1.64e-39 | 5.29e-37 | 3.90e-37 | 106 |
hsa0502253 | Breast | DCIS | Pathways of neurodegeneration - multiple diseases | 114/846 | 476/8465 | 4.74e-20 | 1.53e-18 | 1.13e-18 | 114 |
hsa0501220 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
hsa0502218 | Cervix | CC | Pathways of neurodegeneration - multiple diseases | 128/1267 | 476/8465 | 2.87e-12 | 9.29e-11 | 5.50e-11 | 128 |
hsa05012110 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
hsa0502219 | Cervix | CC | Pathways of neurodegeneration - multiple diseases | 128/1267 | 476/8465 | 2.87e-12 | 9.29e-11 | 5.50e-11 | 128 |
hsa0501225 | Cervix | HSIL_HPV | Parkinson disease | 43/459 | 266/8465 | 6.69e-11 | 6.53e-09 | 5.28e-09 | 43 |
hsa0502224 | Cervix | HSIL_HPV | Pathways of neurodegeneration - multiple diseases | 46/459 | 476/8465 | 8.10e-05 | 1.08e-03 | 8.72e-04 | 46 |
hsa0501235 | Cervix | HSIL_HPV | Parkinson disease | 43/459 | 266/8465 | 6.69e-11 | 6.53e-09 | 5.28e-09 | 43 |
hsa0502234 | Cervix | HSIL_HPV | Pathways of neurodegeneration - multiple diseases | 46/459 | 476/8465 | 8.10e-05 | 1.08e-03 | 8.72e-04 | 46 |
Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PARK7 | SNV | Missense_Mutation | novel | c.473C>A | p.Pro158His | p.P158H | Q99497 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PARK7 | SNV | Missense_Mutation | rs145727915 | c.143N>A | p.Arg48His | p.R48H | Q99497 | protein_coding | deleterious(0) | possibly_damaging(0.456) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
PARK7 | insertion | Frame_Shift_Ins | rs759703272 | c.182_183insA | p.Glu64ArgfsTer5 | p.E64Rfs*5 | Q99497 | protein_coding | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
PARK7 | SNV | Missense_Mutation | novel | c.254N>A | p.Ser85Tyr | p.S85Y | Q99497 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
PARK7 | SNV | Missense_Mutation | rs758016497 | c.56C>T | p.Thr19Met | p.T19M | Q99497 | protein_coding | tolerated(0.17) | benign(0.44) | TCGA-B5-A11J-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PARK7 | SNV | Missense_Mutation | rs371514726 | c.494C>T | p.Ala165Val | p.A165V | Q99497 | protein_coding | deleterious(0.01) | benign(0.264) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PARK7 | SNV | Missense_Mutation | rs182164240 | c.292C>T | p.Arg98Trp | p.R98W | Q99497 | protein_coding | tolerated(0.06) | benign(0.022) | TCGA-BS-A0UA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PARK7 | SNV | Missense_Mutation | novel | c.412N>T | p.His138Tyr | p.H138Y | Q99497 | protein_coding | tolerated(0.24) | benign(0.013) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
PARK7 | SNV | Missense_Mutation | novel | c.355T>G | p.Phe119Val | p.F119V | Q99497 | protein_coding | tolerated(0.52) | benign(0.003) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
PARK7 | SNV | Missense_Mutation | rs768782230 | c.433N>T | p.Arg145Cys | p.R145C | Q99497 | protein_coding | deleterious(0) | probably_damaging(0.948) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |